Eyestem to submit data for approval of phase 2a first-in-human study to DCGI for Eyesight RPE for dry AMD
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 27, 2023
Eyestem will be submitting data for approval of phase 2a first-in-human study for its product named as Eyesight RPE to the Drugs Controller General of India (DCGI) for dry age-related macular degeneration (AMD).
Let's personalize your content